# AI clinical-trial patient recruitment Machine-learning software that scans structured and unstructured electronic health records to identify patients meeting a clinical trial's eligibility criteria and to score candidate trial sites on live population data, replacing the manual chart review that has made patient recruitment the biggest bottleneck before a trial can even begin. Source: https://en.bioecon.ru/technology/ai-clinical-trial-patient-recruitment/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: AI-based matching of patients to clinical trials and data-driven trial site selection | OECD: Biopharmaceutical clinical development | Regulator: FDA (US), EMA (EU)] AI clinical-trial patient recruitment platforms scan structured and unstructured electronic health record data to identify patients meeting a trial's eligibility criteria, replacing hours of manual chart review by clinical-research staff. Deep 6 AI optimizes site selection for clinical trials, letting sponsors base site choices on live population and screening data rather than historical site-performance metrics alone. TriNetX unveiled a conversational AI interface and enhanced API capabilities in January 2026, successfully reducing trial costs and timelines as part of platform enhancements designed to democratize clinical-research analytics. Antidote Technologies' Antidote.me offers AI clinical-trial matching for physicians on an enterprise pay-for-performance model, connecting patients to research directly through referring clinicians. Mendel.ai's software aims to save nurses time in pre-screening, and academic research on end-to-end AI-powered trial-recommendation systems (TrialMatchAI, published in Nature Communications 2026) explicitly frames patient recruitment as a major bottleneck calling for scalable, automated solutions — the problem this whole vendor category exists to solve. Paradigm Health's AI-native solution increased screening capacity by 41% in an August 2026 partnership expanding clinical-trial access with Ochsner Health across the US Gulf South, and the company separately submitted a formal response to FDA's Real-Time Clinical Trials Initiative RFI informed by biopharma sponsors and providers. The key directions of AI clinical-trial patient recruitment are: 1. **EHR-based eligibility matching:** scanning structured and unstructured patient records to automatically identify candidates meeting a trial's specific eligibility criteria. 2. **Data-driven site selection:** scoring candidate trial sites on live patient-population and screening data rather than relying on a site's historical enrollment track record alone. 3. **Physician and patient-facing matching interfaces:** conversational AI and referral tools that connect physicians and patients directly to relevant open trials. 4. **Screening-capacity expansion at health systems:** deploying AI-native screening directly inside health-system workflows to expand the population that can be screened for trial eligibility. ### Sectoral value chain ``` [EHR data access & structuring] ──> [AI eligibility matching] ──> [Candidate patient shortlist] │ (Site-selection scoring) │ [Patient enrollment] <──── [Physician/patient outreach] <─── [Referring-clinician connection] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **EHR data access & structuring** | Accessing and structuring a health system's structured and unstructured patient record data for analysis. | **In:** Raw EHR data.
**Out:** Structured, analyzable patient data. | | **AI eligibility matching** | Applying AI models to identify patients matching a specific trial's eligibility criteria. | **In:** Structured patient data, trial eligibility criteria.
**Out:** Matched candidate list. | | **Candidate patient shortlist** | Compiling the matched candidates into a shortlist for clinical-research staff review. | **In:** Matched candidate list.
**Out:** Reviewed candidate shortlist. | | **Site-selection scoring** | Scoring candidate trial sites on live population and screening data to inform sponsor site selection. | **In:** Aggregated population/screening data.
**Out:** Site-selection score. | | **Referring-clinician connection** | Connecting a matched patient to the trial through their referring physician. | **In:** Reviewed candidate shortlist.
**Out:** Physician referral to trial. | | **Patient enrollment** | Completing the enrollment process for the referred, eligible patient. | **In:** Physician referral to trial.
**Out:** Enrolled trial participant. | Cross-cutting technologies of the sector: - **AI patient-trial matching:** machine-learning software that scans structured and unstructured EHR data to identify patients meeting a trial's eligibility criteria, replacing manual chart review. - **Real-time trial site-selection analytics:** analytics that score candidate trial sites on live patient-population and screening data, letting a sponsor pick sites likely to enroll quickly. --- ## US The United States hosts the leading AI patient-recruitment vendors, several with direct 2026 health-system deployments and platform enhancements. ### Deep 6 AI's site-selection optimization, TriNetX's conversational AI, Paradigm Health's 41% screening-capacity gain - **Deep 6 AI:** optimizes clinical-trial site selection using live population and screening data rather than historical site performance alone. - **TriNetX:** unveiled a conversational AI interface and enhanced API capabilities in January 2026, reducing trial costs and timelines as part of a broader effort to democratize clinical-research analytics. - **Antidote Technologies:** its Antidote.me platform offers AI clinical-trial matching for physicians on an enterprise pay-for-performance model. - **Mendel.ai:** its software aims to save nurses time in pre-screening, applying AI directly to the recruitment bottleneck that academic research has identified as the field's central constraint. - **Paradigm Health:** an August 2026 partnership with Ochsner Health increased screening capacity by 41% across the US Gulf South, and the company formally responded to FDA's Real-Time Clinical Trials Initiative RFI. --- ## CN China is covered qualitatively rather than by a live-screened Chinese vendor: candidate Chinese AI patient-recruitment firms searched during this screen returned only generic market-research reports and academic commentary, not a confirmed named vendor, so no Chinese company is tabled below. ### No confirmed named domestic vendor; market-research coverage describes the category rather than naming a leader - **Market coverage without a named leader:** Chinese-language sources describe the AI clinical-trial patient-recruitment market's growth and trends extensively, but this screen did not surface a specific China-headquartered vendor confirmed by name in a live 2026 source. - **Domestic gap:** no China-headquartered AI patient-recruitment platform confirmed by name was found during this screen. --- ## EU No EU-headquartered vendor cleared the confirmation bar on this screen distinct from the US-headquartered platforms already tabled; European trial sponsors and health systems are served by the same global vendors listed above. ### Served by the same global platforms rather than a distinct EU-headquartered specialist - **EU deployment of global platforms:** the vendors tabled above serve EU clinical-trial sponsors and health systems directly rather than through a confirmed distinct EU-headquartered competitor. - **No distinct EU-headquartered vendor confirmed:** this screen did not surface an EU-headquartered AI patient-recruitment specialist distinct from the platforms already listed. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Deep 6 AI** | 🇺🇸 USA | Site Selection platform | Live population/screening-data-based site scoring | commercial | | **TriNetX** | 🇺🇸 USA | Conversational AI interface, enhanced APIs | Reduced trial costs and timelines (2026) | commercial | | **Antidote** | 🇺🇸 USA | Antidote.me | Physician-facing AI matching, pay-for-performance | commercial | | **Mendel.ai** | 🇺🇸 USA | Mendel.ai pre-screening software | Nurse pre-screening time savings | commercial | | **Paradigm Health** | 🇺🇸 USA | AI-native screening platform | 41% screening-capacity increase at Ochsner Health | commercial | --- ## Tech stack and innovations The AI clinical-trial patient recruitment technology stack combines EHR-scale data access with an increasingly conversational and health-system-embedded AI layer: 1. **Large-scale EHR data matching:** - Deep 6 AI and Mendel.ai apply AI directly to structured and unstructured EHR data to identify eligible patients without manual chart review. 2. **Conversational AI and API expansion:** - TriNetX's January 2026 conversational AI interface and expanded APIs show the category moving toward more accessible, integration-friendly tooling. 3. **Health-system-embedded screening deployment:** - Paradigm Health's direct partnership with a regional health system (Ochsner Health) demonstrates AI screening deployed inside clinical workflows rather than as a standalone research tool, delivering a measured 41% capacity gain. --- ## Value chains and production pipelines ### Industrial pipeline for AI-driven patient recruitment ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. EHR data access & │ ───> │ 2. AI eligibility │ │ structuring │ │ matching │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Site-selection scoring │ <─── │ 3. Candidate patient │ │ │ │ shortlist │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Referring-clinician │ ───> │ 6. Patient enrollment │ │ connection │ │ │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: EHR data access and structuring The platform accesses and structures a health system's structured and unstructured patient record data for AI analysis. #### Stage 2: AI eligibility matching AI models identify patients matching a specific trial's eligibility criteria from the structured data. #### Stage 3: Candidate patient shortlist Matched candidates are compiled into a shortlist for clinical-research staff review. #### Stage 4: Site-selection scoring Candidate trial sites are scored on live population and screening data to inform sponsor site-selection decisions. #### Stage 5: Referring-clinician connection A matched, eligible patient is connected to the trial through their referring physician. #### Stage 6: Patient enrollment The enrollment process is completed for the referred, eligible patient, closing the loop from EHR data to enrolled participant.